Weight loss jab cuts heavy drinking days by 41% in landmark trial

THE INDEPENDENT

A randomized trial has found that weekly semaglutide injections — the active ingredient in weight loss jabs— result in a significant reduction in heavy drinking days, decreasing from an average of 17 to five per month, and a substantial drop in overall alcohol consumption in adults with alcohol use disorder and obesity.